15 Days Price Change
Summary
Once written off as a failed challenger, MSEI is now making a bold second attempt at revival with broker backing, niche strategies, and cleaner governance. But can it really disrupt India's market infra again—or is this just another false dawn? Let's decode the opportunity for investors in the unlisted space.
Once seen as a challenger to NSE and BSE, Metropolitan Stock Exchange of India (MSEI) had a turbulent past—from a bold start in 2008 to being nearly irrelevant for over a decade. Now, with renewed broker backing and strategic product plans, MSEI may finally be on the verge of reclaiming its space in India’s capital market.
MSEI (then MCX-SX) launched in 2008 to break the NSE-BSE duopoly. It quickly gained momentum in the currency derivatives space but fell apart due to the NSEL crisis and promoter exit. Governance issues and NSE’s alleged monopolistic pricing weakened MSEI’s market standing.
From 2014 to 2023, despite regulatory approval and licenses, MSEI couldn’t build market depth. Liquidity dried up, unlisted share prices stayed flat (₹1.5–2), and product launches went nowhere. It became a zombie exchange—alive, but directionless.
SEBI’s 2024 rule allowed only one weekly expiry per index per exchange. This opened up Friday as the only available slot, creating an opportunity for MSEI.
Top brokers like Zerodha, Groww, Share India, and others invested ₹240 Cr, betting that MSEI could own Friday expiries. The unlisted share price surged to ₹14, driven by renewed hope.
SEBI later limited weekly expiries to only Tuesday or Thursday, which were already taken by NSE and BSE. MSEI lost its only strategic product edge, leading to a stock price crash and renewed uncertainty.
With new capital and cleaned-up governance, MSEI is now shifting strategy:
Focusing on cash market, ESG indices, bond platforms, and SME listings
Avoiding reliance on F&O products
Leveraging broker support and innovation to build a differentiated exchange
MSEI’s revival is no longer based on hype, but on product innovation and niche positioning
Backing from top brokers adds legitimacy but not guaranteed liquidity
It's a high-risk, high-reward unlisted play for those tracking alternative market infra stories
Regulatory dependency remains a double-edged sword
For investors looking to tap into this story before any formal IPO announcement, platforms like Sharescart.com offer easy access to verified sellers and updated MSEI share prices. You can track valuations, broker activity, and make informed decisions directly from our curated exchange listings.
MSEI may never rival NSE or BSE in scale, but its second comeback attempt is grounded in better strategy and stronger backing. For investors in the unlisted space, it’s a story worth tracking—not for quick flips, but for potential long-term transformation in India’s exchange landscape.
Sell or Purchase Share (Tentative Price)
Company | Industry | Stock P/E | P/B | Company rating | MCAP (in Cr.) | Current Price |
---|---|---|---|---|---|---|
Pharmeasy | e-Commerce | -2.2 | 2.1 | 5463 | 8.5 | |
Reliance Retail | Retailing | 141.5 | 23 | 698659 | 1400 | |
Orbis Financial | Finance - Investment | 47.4 | 9.7 | 6695 | 550 |
How Your Money Can Grow With Us